{"name":"Generex Biotechnology Corp.","slug":"generex-biotechnology-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Buccal insulin spray","genericName":"Buccal insulin spray","slug":"buccal-insulin-spray","indication":"Type 1 diabetes","status":"phase_2"},{"name":"Generex Oral-lyn™","genericName":"Generex Oral-lyn™","slug":"generex-oral-lyn","indication":"Type 1 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"Buccal insulin spray","genericName":"Buccal insulin spray","slug":"buccal-insulin-spray","phase":"phase_2","mechanism":"Insulin receptor agonist","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"Generex Oral-lyn™","genericName":"Generex Oral-lyn™","slug":"generex-oral-lyn","phase":"phase_3","mechanism":"Oral-lyn is an oral insulin formulation that delivers insulin through the buccal mucosa to lower blood glucose in diabetes patients.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOMWZwZTRvSVZqeXNldzRSSHd6QnFfb21nTGp2NUxwVV9PZTZpNng0OXVabWVzTjY1VHFITmxxbFpKcmpJaE1URnZTbXIyWGhLM0taUVdoSVRObjZEZFhyeGFHdnVCV0RvZVZVTEhSTGtuenhPRHI1X050bHNVVXQ2MF84YXJQNWRIZVZNcC1WczVoVzFESFhoNlk2MHV1Vy1HUEFhSEtoOUNaVU5fcmtuOWpQb0ZjTFd6azJCNVFweXVwVkUxWmp2X29NcDU3Q3AyUnNHLVVpUUc5X0MzRE1OLVBmcnpsMXdVb2d4dElBaw?oc=5","date":"2026-03-25","type":"pipeline","source":"Barchart.com","summary":"Projecting the Global Drug Delivery Devices Market Size to Expand at a 5.07% CAGR Through 2032, DelveInsight Analysis - Barchart.com","headline":"Projecting the Global Drug Delivery Devices Market Size to Expand at a 5.07% CAGR Through 2032, DelveInsight Analysis","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNMnROM0hSTThlWGhDcEVjWE8wd3ctekx1ZVV2ZEE0bUVLSmxRektVZmJOSHFUTUdYbVE5VzNSaEZoaUs2QjY0dkZfX0oyLUwySEhGVGlHaHNFN0RWTHZNalRXb3pZR3lmYkdyVnpVVGdkSjZzb08teHVySWFjTDczNnF3M21qSVdhdnpGZHVGN1hKd2pfOS01ZEx5a3J3YjZGWGZfV3djNndaUjZLTG13VWJPZEpXVE1xZHU0OWstY1d1a1piT3dSZnEyMWdvQjIzUHZrVzV3alpqaF9qM2o5b3M4MENVU04wVU54aDZWZ2llVkxUOUJBbWllbW1VTGRvY3F2R3ZfOUtPNXhKWEV0bU55a282b25ZVWVxSVVFXzRMdXhvaG1uVEdvT0xpLTZtSDB2N0lrZw?oc=5","date":"2026-03-04","type":"pipeline","source":"PR Newswire UK","summary":"Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight - PR Newswire UK","headline":"Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOZUowRnQ2SklnQnA5N2UyZUR2NmM5MzRIZ2dfWG56ZGNnZlBEWHNacnRPejlNc0NHUHlFY2RRbkNSRVd4WkYzTHFfbEVEVnJyNE1OVHhoZ1V2NzE3c1ZvTno1dk40WVA1NE13OG1aV0k5b3V3a2JhMzZkWHUxcnEtbkFvT3FGM3g4N2VKdGt3UHV5bUVxYi1sSHBOMlhsMnM?oc=5","date":"2020-12-07","type":"pipeline","source":"KLSE Screener","summary":"Two more firms join the vaccine distribution club - KLSE Screener","headline":"Two more firms join the vaccine distribution club","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNMlVyeWFVdFBWa1JGU290c2FrMHFNVG1HajhTY1lkUENXWFdiOHQ4RWI3cEdqNk1BOGNQMUFyeW5lNFZhNlByT3VjSmhWdWJjeTN0Tm85YkVEUFJFWEw3S1R6Y0FRbVBBTzdKbHdsSWp0bGVrZDBMSTlLUWc4WERMUk9qbm5xRmNnc1hQRm5PU0NacXlsX0xXT01SVVY0NzR0bGNNZ3lfdWZ0bzZ2NXZOLQ?oc=5","date":"2020-09-24","type":"deal","source":"The Malaysian Reserve","summary":"Solution Group unit inks deal with CanSino for vaccine distribution - The Malaysian Reserve","headline":"Solution Group unit inks deal with CanSino for vaccine distribution","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFAzU1RCcVlnZTJkajluWG0yT21HeTVkVTdGU05MM0kzNnh6MG92eVJVYWtjdUF4NVUwcmVxcTJUMVNKMW9jdTJ4LTYyM21VNGYxYlhtaDBtUlBmYmVqVEpXWlowR25SYVNZbFhHS0htbm_SAXBBVV95cUxQTmlVb055MmN6b1RXTmsycGZpV1NydmtkSW9RUm5CSDBYaTNZbTZqUm5CVzVLNkhDZEcyQW50SDJEdjEwNXdMSUV4X3JkbWVza3Zacm5VQXo4UXZhb0pISnZ4SnA5Yjl0RUNxNWx6NUtj?oc=5","date":"2019-12-18","type":"pipeline","source":"Miami Herald","summary":"Miramar biotech company Generex issues shareholder alert alleging illicit activity - Miami Herald","headline":"Miramar biotech company Generex issues shareholder alert alleging illicit activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE52REZybjNHeUg4WUNWdDU5VzVEc1RRNkFXaTJCUnNvdlBIRE81enk3UE03YnZHVWhlT1VzamVJVnFHTll1MU0xOEVLc1BsUXlhTzRvS3owN1pOSGRidUs4ZkgtNDB4R2l6MVBn?oc=5","date":"2019-06-15","type":"pipeline","source":"Market.us","summary":"Oral Proteins and Peptides Market Size Analysis | CAGR of 10.1% - Market.us","headline":"Oral Proteins and Peptides Market Size Analysis | CAGR of 10.1%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOVVNSUEN6c0Z3eW9jelZDTDRmcktDOUdPYkttMWJZS25LWEZSVmFMOHBUc3c2WWhYb1NvZjNHSEw5dzRqRjh0bHRJaGt0bzdnNGtPSEVab2V4YVZnaEpXeVNyTGU0c255WjdGYWs0NVdvbjBaRkpiQ005N1RYUlJBZmFpWVVIa2hOQU5JcG9HNjl6MlpkckdEMXNOZnJEbFE?oc=5","date":"2018-01-02","type":"pipeline","source":"Contract Pharma","summary":"Generex Receives $700M Payment from Shenzhen BioScien - Contract Pharma","headline":"Generex Receives $700M Payment from Shenzhen BioScien","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOMW96dVhPVkZReUI1ckdsY2FGeXBzeGVCdmpodlQ3RGNGMmRqZE1LRWRHV1N1MElReGdtUlZGWFVMaG5IVTVQNDF3cVZGSlJ2UmZZQmg0bFZxOC1RRlRtd0s3aFJNeXRIckZNdDNLTHd1WG9sbE5OdjZBZ0t0eC11VlJuUktINTRQbmdaWUx0MjN4dHVXZlE?oc=5","date":"2016-12-31","type":"pipeline","source":"Pharmaceutical Online","summary":"Lilly and Generex to develop buccal form of insulin - Pharmaceutical Online","headline":"Lilly and Generex to develop buccal form of insulin","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}